ReviewJACC. Asia2022
Stroke Prevention in Atrial Fibrillation: A Scientific Statement of
Review in JACC. Asia, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.
- Oral Anticoagulation Therapy in Atrial Fibrillation Patients with Intermediate Stroke Risk: A Systematic Review and Meta-Analysis.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisPooled it
- The Effectiveness of Digital Animation-Based Multistage Education for Patients With Atrial Fibrillation Catheter Ablation: Randomized Clinical Trial.Journal of medical Internet research · 2025Trial
- Left Atrial Appendage Closure in Patients with Atrial Fibrillation and Intermediate-to-Borderline High Cardiovascular Risk: A Retrospective Propensity Match Cohort Study.Journal of cardiovascular development and disease · 2026Article
- The Triglyceride-Glucose Index: A Clinical Tool to Quantify Insulin Resistance as a Metabolic Myocardial Remodeling Bridge in Atrial Fibrillation.Biomedicines · 2025Review
- Patient Outcomes in Very Elderly Patients With Non-Valvular Atrial Fibrillation - ANAFIE Registry.Circulation reports · 2024Article
- Atrial fibrillation: stroke prevention.The Lancet regional health. Europe · 2024Review
- Evaluation of disease burden and symptom scores in patients with acute atrial fibrillation in the emergency department.World journal of emergency medicine · 2024Article
- Differences between atrial fibrillation diagnosed before and after stroke: A large real-world cohort study.PloS one · 2024Article
- Survey of Using Oral Anticoagulants in Patient with Non-valvular Atrial Fibrillation.Medical archives (Sarajevo, Bosnia and Herzegovina) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 7 institutions in 8 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia and is associated with substantial increases in the risk for stroke and systemic thromboembolism. With the successful introduction of the first non-vitamin K antagonistdirect oral anticoagulant agent (NOAC) in 2009, the role of vitamin K antagonists has been replaced in most clinical settings except in a few conditions for which NOACs are contraindicated. Data for the use of NOACs in different clinical scenarios have been accumulating in the past decade, and a more sophisticated strategy for patients with AF is now warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.